Tariffs have sent shockwaves through global markets and disrupted businesses across a wide range of industries. Amid these trade tensions, companies face unprecedented challenges in supply chain management, pricing strategies, and long-term planning.

Something big is happening in American hospitals—and it’s not another shiny new device or a blockbuster drug. It’s a quiet, behind-the-scenes transformation driven by smart software that’s getting better at understanding how doctors think, how patients behave, and how diseases unfold.

For companies and investment funds following the Brazilian economy, there are a wealth of current and short-term indicators available. But in order to make sense of the data, it is necessary to lift the bonnet and have a deeper look at the workings of the economy that takes a longer-term perspective.

The global hemoglobin A1c (HbA1c) testing market is on the brink of significant transformation and growth, according to a new report Hemoglobin A1c (HbA1c) Testing Global Market Report 2024 by The Business Research Company with market data from 2019 to 2034.

How do country-specific tariff rates impact different segments of the US manufacturing sector?

This question has manufacturers scrambling as trade policy shifts ripple through global supply chains.

As artificial intelligence (AI) continues its relentless march into every corner of industry, a quieter revolution is reshaping the foundations of computing—deep inside the world’s data centers.

The data governance industry is growing rapidly as more organizations understand the importance of effective data management.

The demand for battery energy storage systems (BESS) is surging as the world shifts toward renewable energy. However, managing heat in large-scale batteries is a major challenge.

Micromobility businesses, such as scooter rentals, are expanding rapidly due to increased urbanization and government-supported sustainability initiatives. This growth has created a lucrative opportunity for market players to capitalize on.

The $38 billion U.S. commercial weight loss market is 15% larger than in 2020, but has had to pivot to adjust to huge competition from the popular GLP-1 drugs.